The value of Dymista®

Multiple components in Dymista®

Multiple components contribute to the overall product effectiveness of Dymista®: the two active ingredients and the formulation.3

Dymista® components

Dymista® clock

‘Dymista®’s dual therapy has been found to control symptoms more effectively and faster in patients with moderate and severe allergic rhinitis than intranasal azelastine or fluticasone propionate alone.’ 4,5

Superior efficacy

Dymista® has been shown to be twice as effective as fluticasone propionate or azelastine alone at treating the entire rhinitis symptom spectrum.6,7

In a randomized, double-blind, placebo-controlled, 2-week trial involving 779 patients with moderate-to-severe seasonal allergic rhinitis, Dymista® administered as one spray to each nostril twice-daily provided greater nasal and ocular symptom improvement than azelastine (INAH) or fluticasone propionate (INS) administered alone (one spray to each nostril twice-daily).7

DYMISTA® (MP29-02) RESULTED IN GREATER IMPROVEMENT IN NASAL SYMPTOMS OF ALLERGIC RHINITIS THAN INS OR INAH ALONE7
Dymista® efficacy comparison graph 1

Adapted from Meltzer, et al. 2012.7

DYMISTA® (MP29-02) RESULTED IN GREATER IMPROVEMENT IN OCULAR SYMPTOMS OF ALLERGIC RHINITIS THAN INS OR INAH ALONE7
Dymista® efficacy comparison graph 2

Adapted from Meltzer, et al. 2012.7

Dymista® clock
By Day 1 almost twice as many Dymista® patients were symptom free. After 1 month, 71.1% of patients experienced 100% rTNSS reduction (60.3% for FP), and did on a median of 9 days faster (P=.0024).’ 8

Real life symptom control

Dymista®’s clinical efficacy has been confirmed in real life.7
Dymista® symptom control

Dymista® clock
After 1 day of Dymista® treatment, patients’ symptoms scores were lower than those prior to treatment and were in the “well-controlled” zone by day 4.

Five-minute onset of action

Dymista® provides a 5-minute onset of action,10 giving your patients rapid symptom relief.

In a randomized, placebo-controlled, double-blind, double-dummy, 3-period crossover trial of 82 patients with a history of allergic rhinitis and a positive skin prick test to ragweed pollen, subjects had allergic rhinitis symptoms induced by ragweed pollen in an allergen environmental exposure chamber. Patients received single-dose Dymista®, or the two medications oral loratadine and intranasal fluticasone propionate (FP + loratadine), or placebo, and were monitored for 4 hours.10

Dymista® onset of action graph
  • Dymista® reduced TNSS at 5 minutes and throughout the 4-hour assessment period (p<0.05 vs. placebo). Loratadine plus FP was not significantly different from placebo until 150 minutes (p<0.05).10
  • Dymista® was superior over the entire assessment period compared with placebo (p<0.001).10

Dymista® is suitable for long term use

For patients to get the full therapeutic benefit, regular usage of Dymista® nasal spray is essential, and Dymista® is suitable for long-term use.11

Treatment should be continued for as long as the patient is exposed to the allergen(s).

A 52-week open-label study showed Dymista® has a large therapeutic spectrum, covering not only seasonal allergic rhinitis but also perennial allergic rhinitis with consistent superiority over an intranasal corticosteroid.6

Adding monetary value

Proper adherence to the primary care pathway using currently available medications, such as Dymista®, can potentially save money within allergic rhinitis management in the UK.8 An estimated £136-212 per patient could be saved by prescribing medicines like Dymista® instead of referring to secondary care. This is in addition to a saving of £45 for every repeat consultation with the GP.9

Dymista® clock
‘Dymista® can have monetary benefits compared with separate INCS and INAH treatments, and help prevent costly referrals to secondary care.’ 8,11

Recommended in national and international guidelines

Dymista® is now included in national and international guidelines and recommendations:

References

  • Scadding GK, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy 2017; 47(7): 856-889.
  • Scottish Medicine Consortium (SMC). Available at https://www.scottishmedicines.org.uk/medicines-advice/azelastine-hydrochloride-plus-fluticasone-propionate-dymista-abbreviatedsubmission-92113/. Last accessed: November 2018.
  • Dymista® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/9450. Last accessed: November 2018.
  • Derendorf H, et al. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Br J Clin Pharmacol. 2012; 74(1): 125-133.
  • Meltzer E, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013; 161(4): 369-77.
  • Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012; 129: 1282-1289.
  • Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc. 2012; 33: 324-332.
  • Price D, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol. 2013; 23(7): 495-503.
  • Klimek L, Bachert C, Mösges R, Munzel U, Price D, Virchow JC, et al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: Results from a noninterventional study. Allergy Asthma Proc. 2015; 36: 40-47.
  • Bousquet J, et al. Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber. J Allergy Clin Immunol Pract. 2018; 6(5): 1726-1732.
  • Lipworth B, Newton J, Ram B, Small I, Schwarze J: An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel. NPJ Prim Care Respir Med. 2017; 27: 3.

The website you are trying to access is designed for healthcare professionals in the UK, the content is not designed for the general public.

Are you a UK healthcare professional?

YES
NO